Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ina Rhee, M.D., Ph.D.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
42 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
St Leonards, New South Wales, Australia
- Facility name not stated
Herston, Queensland, Australia
- Facility name not stated
Woodville South, South Australia, Australia
- Facility name not stated
Brno, Czechia
- Facility name not stated
Ostrava - Poruba, Czechia
- Facility name not stated
Le Mans, France
- Facility name not stated
Lyon, France
- Facility name not stated
Marseille, France
- Facility name not stated
Marseille, France
- Facility name not stated
Paris, France
- Facility name not stated
Saint-Herblain, France
- Facility name not stated
Toulouse, France
- Facility name not stated
Essen, Germany
- Facility name not stated
Gauting, Germany
- Facility name not stated
Großhansdorf, Germany
- Facility name not stated
Halle, Germany
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Székesfehérvár, Hungary
- Facility name not stated
Tatabánya, Hungary
- Facility name not stated
Bydgoszcz, Poland
- Facility name not stated
Gdansk, Poland
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Hot Springs, Arkansas, United States
- Facility name not stated
Santa Monica, California, United States
- Facility name not stated
Orlando, Florida, United States
- Facility name not stated
Port Saint Lucie, Florida, United States
- Facility name not stated
St. Petersburg, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Marietta, Georgia, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Wichita, Kansas, United States
- Facility name not stated
Burnsville, Minnesota, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Albany, New York, United States
- Facility name not stated
Columbus, Ohio, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Hershey, Pennsylvania, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Austin, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2011
- Primary completion
- 28 Feb 2013
- Completion
- —
- Last update posted
- 2 Nov 2016
- Registered enrollment
- 104
- Registry id
- NCT01366131
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.